Provectus Biopharmaceuticals

Company snapshot

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.

• 12 active pipeline program(s) linked via ClinicalTrials.gov.
• 29 US patent(s) indexed to this assignee profile.
• 12 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Provectus Biopharmaceuticals. Not investment advice.

• Peer + 0 momentum

  Regeneron UK

  TA overlap score 40

• Peer + 0 momentum

  Universal Integrated

  TA overlap score 37.8

• Peer + 0 momentum

  Arcutis Biotherapeutics

  TA overlap score 35.4

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Nektar Therapeutics UK

  TA overlap score 31.4

• Peer + 0 momentum

  Syndax Pharmaceuticals

  TA overlap score 29.4

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 28

• Peer + 0 momentum

  Prime Medicine

  TA overlap score 23.4

• Peer + 0 momentum

  IO Biotech

  TA overlap score 23.2

• Peer + 0 momentum

  Peking University Biologics

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Provectus Biopharmaceuticals.

1. Jun 8, 2026 Clinical update

   Rose bengal disodium — Phase 1

2. Jun 8, 2026 Clinical update

   Topical Rose Bengal, 0.005% — Phase 2

3. Jun 8, 2026 Clinical update

   PV-10 (rose bengal disodium, 10%) — Phase 1

4. Jun 8, 2026 Clinical update

   PV-10 — Phase 2

5. Jun 8, 2026 Clinical update

   PV-10 (10% rose bengal disodium) — Phase 2

View all clinical trial activity →

• What is Provectus Biopharmaceuticals?

  Provectus Biopharmaceuticals is a biotech organization headquartered in Knoxville, USA. It trades on NYSE under ticker PVCT. Primary therapeutic focus areas include Melanoma, Psoriasis, Atopic Dermatitis, Plaque Psoriasis, Cancer Metastatic to the Liver. NovaPharmaNews links 12 c

• Is Provectus Biopharmaceuticals publicly traded?

  Yes. Provectus Biopharmaceuticals is listed with ticker PVCT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Provectus Biopharmaceuticals develop or market?

  We link 5 drug profile(s) where Provectus Biopharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc#company-drugs.

• What are the latest developments for Provectus Biopharmaceuticals?

  In the last 12 months our linked public records show 12 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Provectus Biopharmaceuticals focus on?

  Provectus Biopharmaceuticals focuses on Melanoma, Psoriasis, Atopic Dermatitis based on our analysis of their pipeline programs and drug development activities.